GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
GO:00425948 | Cervix | CC | response to starvation | 46/2311 | 197/18723 | 1.24e-05 | 2.59e-04 | 46 |
GO:00316698 | Cervix | CC | cellular response to nutrient levels | 49/2311 | 215/18723 | 1.32e-05 | 2.68e-04 | 49 |
GO:00075695 | Cervix | CC | cell aging | 34/2311 | 132/18723 | 1.92e-05 | 3.53e-04 | 34 |
GO:00714798 | Cervix | CC | cellular response to ionizing radiation | 22/2311 | 72/18723 | 3.47e-05 | 5.60e-04 | 22 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:00714786 | Cervix | CC | cellular response to radiation | 41/2311 | 186/18723 | 1.41e-04 | 1.71e-03 | 41 |
GO:00102126 | Cervix | CC | response to ionizing radiation | 34/2311 | 148/18723 | 2.23e-04 | 2.53e-03 | 34 |
GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
GO:00510528 | Cervix | CC | regulation of DNA metabolic process | 65/2311 | 359/18723 | 9.25e-04 | 7.84e-03 | 65 |
GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WRN | SNV | Missense_Mutation | novel | c.1940N>T | p.Ser647Leu | p.S647L | Q14191 | protein_coding | tolerated(0.09) | benign(0.022) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
WRN | SNV | Missense_Mutation | novel | c.749N>G | p.Met250Arg | p.M250R | Q14191 | protein_coding | deleterious(0) | benign(0.124) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
WRN | SNV | Missense_Mutation | novel | c.2260C>G | p.Leu754Val | p.L754V | Q14191 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
WRN | SNV | Missense_Mutation | novel | c.1335N>C | p.Glu445Asp | p.E445D | Q14191 | protein_coding | tolerated(0.1) | benign(0.216) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WRN | SNV | Missense_Mutation | novel | c.1416N>C | p.Glu472Asp | p.E472D | Q14191 | protein_coding | tolerated(0.21) | benign(0.174) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WRN | SNV | Missense_Mutation | | c.1475N>A | p.Ser492Tyr | p.S492Y | Q14191 | protein_coding | deleterious(0) | possibly_damaging(0.744) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WRN | SNV | Missense_Mutation | rs752650803 | c.1988N>T | p.Thr663Met | p.T663M | Q14191 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
WRN | SNV | Missense_Mutation | | c.2122N>G | p.Ser708Ala | p.S708A | Q14191 | protein_coding | deleterious(0.01) | possibly_damaging(0.681) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WRN | deletion | Frame_Shift_Del | rs778872619 | c.3376delN | p.Ser1128ValfsTer34 | p.S1128Vfs*34 | Q14191 | protein_coding | | | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
WRN | SNV | Missense_Mutation | rs756575284 | c.197N>T | p.Ser66Leu | p.S66L | Q14191 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | NSC-155693 | CHEMBL68096 | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | EPIRUBICIN HYDROCHLORIDE | EPIRUBICIN HYDROCHLORIDE | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | CEFAMANDOLE SODIUM | CEFAMANDOLE SODIUM | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | 3-O-METHYLQUERCETIN | 3-O-METHYLQUERCETIN | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | SJ000082806 | CHEMBL494668 | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | 3,4,5,6-TETRACHLORO-[1,2]BENZOQUINONE | CHEMBL364729 | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | MMV006513 | CHEMBL585622 | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | NSC-130813 | CHEMBL463783 | |
7486 | WRN | CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | | CAMPTOTHECIN | CAMPTOTHECIN | 17303082 |